Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 June 2019Website:
http://www.akerotx.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 17:02:15 GMTDividend
Analysts recommendations
Institutional Ownership
AKRO Latest News
LOS ANGELES--(BUSINESS WIRE)--AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Akero securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period").
LOS ANGELES , June 25, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ: AKRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) common stock between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On October 10, 2023, Akero announced the results of.
NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the “Class Period”), of the important June 25, 2024 lead plaintiff deadline.
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for potential violations of the federal securities laws.
LOS ANGELES--(BUSINESS WIRE)--AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
SAN DIEGO, CA / ACCESSWIRE / June 24, 2024 / The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the "Class Period"), have until this upcoming Tuesday, June 25, 2024 to seek appointment as lead plaintiff. Captioned Klobus v.
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ: AKRO) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Akero securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period").
What type of business is Akero Therapeutics?
Akero Therapeutics Inc. is a company specializing in cardiometabolic non-alcoholic steatohepatitis (NASH). The company focuses on developing drugs aimed at restoring metabolic balance and improving the overall health of patients with NASH. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to target the processes underlying the pathogenesis of NASH, with the potential to restore healthy liver fat metabolism, reduce hepatocyte stress, alleviate inflammation, and eliminate fibrosis. Efruxifermin is being developed in a separate cohort studying the treatment of patients with compensated liver cirrhosis (F4).
What sector is Akero Therapeutics in?
Akero Therapeutics is in the Healthcare sector
What industry is Akero Therapeutics in?
Akero Therapeutics is in the Biotechnology industry
What country is Akero Therapeutics from?
Akero Therapeutics is headquartered in United States
When did Akero Therapeutics go public?
Akero Therapeutics initial public offering (IPO) was on 20 June 2019
What is Akero Therapeutics website?
https://www.akerotx.com
Is Akero Therapeutics in the S&P 500?
No, Akero Therapeutics is not included in the S&P 500 index
Is Akero Therapeutics in the NASDAQ 100?
No, Akero Therapeutics is not included in the NASDAQ 100 index
Is Akero Therapeutics in the Dow Jones?
No, Akero Therapeutics is not included in the Dow Jones index
When does Akero Therapeutics report earnings?
The next expected earnings date for Akero Therapeutics is 09 August 2024